

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
02252	MEDBOT-B	2021/10/26	2021/11/01	2021/11/02

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2021/10/21-2021/10/26
Closing Time for Margin Application	2021/10/25 2:00pm
Subscription Fee	HKD 100
Days For Margin Financing	6 days
Indicative Interest Rate	2.08% (0.25% deductible [^]) [^] Eligible new and existing customers who use the electronic direct debit authorization (eDDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)

Share Offer Highlights

Total Number of Offer Shares:	36,200,000 H Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	3,620,000 H Shares (subject to adjustment)
- Number of Placing Shares:	32,580,000 H Shares (including 1,810,000 Reserved Shares under the Preferential Offering) (subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 36.00-43.20 per Share
2020 Historical P/E ratio:	-
Sponsor:	J.P.Morgan, CICC

Company Overview

Founded in 2015, MedBot is a top-tier surgical robot company dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures. They are currently developing one Core Product, Toumai® (圖邁®) Laparoscopic Surgical Robot, or Toumai, for application in urologic surgery and will seek to expand its application to gynecologic, thoracic and general surgeries. As of the Latest Practicable Date, They owned two material patents, namely robotic arm and transmission mechanism and surgical instruments, relating to Toumai. Their three flagship products, Toumai, DFVision® (蜻蜓眼®) 3D Electronic Laparoscope and Honghu (鴻鵠®) Orthopedic Surgical Robot, have all been admitted to the NMPA's innovative medical device special review and approval procedure (known as the "Green Path"). Toumai and Honghu are at the registration approval stage, and DFVision has recently received NMPA approval. Other than the flagship products, they also have six product candidates at various stages of development. They are the only company in the industry worldwide with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, according to Frost & Sullivan.

For the year ended December 31, 2019 and 2020, the Company's net losses were RMB 69.80 mn, and RMB 208.87 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888



Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He
District, Guangzhou

(020) 8981 7463

Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan

(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.